CUROSURF is a pulmonary surfactant used in the treatment of neonatal respiratory distress syndrome (RDS), primarily in premature infants. This medication is derived from natural surfactant materials and contains phospholipids, neutral lipids, and surfactant-associated proteins. CUROSURF works by reducing the surface tension within the lungs, thereby facilitating easier breathing and improving oxygen exchange. It is typically administered directly into the trachea through a tube in a clinical setting under the supervision of healthcare professionals. CUROSURF has been instrumental in significantly improving the survival rates and outcomes of premature infants suffering from RDS, making it a critical component in neonatal care.